Repotrectinib
As of the edition of 20 October 2026, Repotrectinib is a small molecule: marketed, first approved in 2023 (US); acts on NTRK2, NTRK3 and ROS1; US protection ends in 2036.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Marketed; latest approval 2025
- Kind
- Small molecule
- Brand name
- Augtyro
- First approved
- 15 November 2023 (US)
- Approvals on record
- 5 in 3 regions
- Holder of the most recent approval
- Bristol Myers Squibb
- Registered trials
- 17, 4 stopped early
- Disease areas
- Cancer; Lungs and airways; Blood and lymph; Digestive system; Immune system; Hormones
US protection
US protection ends in 2036.
The last listed US drug-substance patent ends in 2036. The application that gives this date is held by Bristol Myers Squibb.
This is the US only, and it is not the date generics or biosimilars can enter.
The exact date and the listings behind it
In the product10 listings count towards this date. The exact date and each listing are in the product.
See the exact date and the 10 listings behind itRequest access. Nothing is shown until you do.
Companies that need a new molecule because of this drug
3 company-target rows on route B because of this drug.
Companies on route B for this drug
In the product3 company-target rows are on route B because of Repotrectinib.
See the 3 company-target rows on route B for this drug, with the facts behind eachRequest access. Nothing is shown until you do.
Targets
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase not stated | 3 | 0 | 2 | 0 |
| Phase 1 | 6 | 3 | 0 | 2 |
| Phase 2 | 7 | 0 | 5 | 2 |
| Phase 3 | 1 | 0 | 1 | 0 |
| All trials | 17 |
Who has held its approvals
| Company | Role | Years |
|---|---|---|
| Bristol Myers Squibb | Originator and Lead sponsor of trials | 2017 to now |